Abstract: There is disclosed an endotracheal tube which has a minimal cross-sectional profile for easy viewing of anatomical features during intubation. After the tube is placed into the trachea, the tube is adapted to increase the diameter. In this manner the tube diameter may be expanded to allow for decreased Work of Breathing (WOB) for patient, while not having so large a diameter as to cause tracheal discomfort.

Abstract: There is disclosed an endotracheal tube which has a minimal cross-sectional profile for easy viewing of anatomical features during intubation. After the tube is placed into the trachea, the tube is adapted to increase the diameter. In this manner the tube diameter may be expanded to allow for decreased Work of Breathing (WOB) for patient, while not having so large a diameter as to cause tracheal discomfort.

Abstract: There is disclosed an endotracheal tube which has a minimal cross-sectional profile for easy viewing of anatomical features during intubation. After the tube is placed into the trachea, the tube is adapted to increase the diameter. In this manner the tube diameter may be expanded to allow for decreased Work of Breathing (WOB) for patient, while not having so large a diameter as to cause tracheal discomfort.

Abstract: There is disclosed an endotracheal tube which has a minimal cross-sectional profile for easy viewing of anatomical features during intubation. After the tube is placed into the trachea, the tube is adapted to increase the diameter. In this manner the tube diameter may be expanded to allow for decreased Work of Breathing (WOB) for patient, while not having so large a diameter as to cause tracheal discomfort.

Abstract: There is disclosed an endotracheal tube which has a minimal cross-sectional profile for easy viewing of anatomical features during intubation. After the tube is placed into the trachea, the tube is adapted to increase the diameter. In this manner the tube diameter may be expanded to allow for decreased Work of Breathing (WOB) for patient, while not having so large a diameter as to cause tracheal discomfort.

Abstract: There is disclosed an endotracheal tube which has a minimal cross-sectional profile for easy viewing of anatomical features during intubation. After the tube is placed into the trachea, the tube is adapted to increase the diameter. In this manner the tube diameter may be expanded to allow for decreased Work of Breathing (WOB) for patient, while not having so large a diameter as to cause tracheal discomfort.

Abstract: The invention relates to target-associative tags incorporating cysteamine as the target-associative moiety. The invention further relates to a method for producing a target-associative tag by addition of cysteamine as the target-associative moiety to another molecule or entity having a property or properties useful in discriminating or selecting between members of a set, where such properties could include, for example, fluorescence, mass, affinity, reactivity, size, absorbance, magnetism, subatomic spin characteristics, or an ability to associate specifically or preferentially with certain structures. The invention further relates to a method for analyzing, identifying, or purifying phosphorylated proteins or phosphorylated protein fragments using a tag having the properties of both fluorescence and affinity.

Abstract: The invention relates to target-associative tags incorporating cysteamine as the target-associative moiety. The invention further relates to a method for producing a target-associative tag by addition of cysteamine as the target-associative moiety to another molecule or entity having a property or properties useful in discriminating or selecting between members of a set, where such properties could include, for example, fluorescence, mass, affinity, reactivity, size, absorbance, magnetism, subatomic spin characteristics, or an ability to associate specifically or preferentially with certain structures. The invention further relates to a method for analyzing, identifying, or purifying phosphorylated proteins or phosphorylated protein fragments using a tag having the properties of both fluorescence and affinity.

Abstract: Novel inhibitors of angiotensin coverting enzyme having the general formula R - A - S - Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

Abstract: Methods for the alkylation of substituted amines with trifluorate esters is disclosed.

Abstract: Novel inhibitors of angiotensin converting enzyme are disclosed which have the general formula ##STR1## wherein R.sub.1 and/or R.sub.3 form complex amides and imides thereof, R.sub.4 and R.sub.5 form with --N--C-- a 4-6 membered ring structure as described and the other R substituents are selected from a variety of disclosed groups.

Abstract: Novel thiolester compounds are disclosed which are orally effective angiotensin converting enzyme inhibitors useful in the treatment of mammalian hypertension. They have the formula,R.sub.1 -A.sub.1 -S-Z,wherein Z denotes -B-A.sub.2, R.sub.1 is H or an acyl group, A.sub.1 is a carboxylic acid containing at least one amino or imino -N-, A.sub.2 is a carboxylic acid containing at least one amino or imino -N- or a lower alkyl ester or amide thereof, B is a 2-4 carbon backbone chain in mercapto linkage to S which includes a carbonyl or sulfonyl group joined in carboxamido or sulfonamido linkage, respectively, to A.sub.2.Preferably A.sub.2 includes a 4-6 membered C-N ring or a 5 membered ring of one N, one S and 3 C atoms.

Abstract: Novel inhibitors of angiotensin converting enzyme having the general formula R - A - S - Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

Abstract: ACE inhibitors containing amino acid esters of thiopropanoyl-L-3,4-dehydroproline are disclosed.

Abstract: Novel compounds are disclosed as potent inhibitors of angiotensin converting enzyme and as orally effective antihypertensive agents.

Abstract: Novel compounds are disclosed as potent inhibitors of angiotensin converting enzyme and as orally effective antihypertensive agents.

Abstract: The compounds, N-[3-(benzoylphenylalanylthio)-2-D-methylpropanoyl]-L-proline (I), N-(2-benzoylphenylalanylthiopropanoyl)-L-proline (II) and N-(3-benzoylphenylalanylthiopropanoyl)-L-proline (III) are disclosed. These compounds are potent inhibitors of serum angiotensin converting enzyme.

Abstract: Novel compounds are disclosed as potent inhibitors of angiotensin converting enzyme and as orally effective antihypertensive agents.

Abstract: Inhibitors of angiotensin converting enzyme which have the formula: ##STR1## wherein R is hydrogen, formyl, acetyl propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl, pyro-L-glutamyl-L-lysyl, L-lysyl, L-arginyl or pyro-L-glutamyl;A is L-phenylalanyl, D-phenylalanyl, D,L-alanyl, D-alanyl, D,L-tryptophyl, D-tryptophyl, D,L-tyrosyl, D-tyrosyl, D,L-isoleucyl, D-isoleucyl, D,L-leucyl, D-leucyl, D,L-histidyl, D-histidyl, D,L-valyl, or D-valyl, the .alpha.-amino group thereof being in amide linkage with R;R.sub.1 is hydrogen or methyl;R.sub.2 is L-proline, L-3,4-dehydroproline, D,L-3,4-dehydroproline, L-3-hydroxyproline, L-4-hydroxyproline, L-thiazolidine-4-carboxylic acid, or L-5-oxo-proline, the imino group thereof being in imide linkage with the adjacent ##STR2## and, n is 0 or 1, such that when n is 0, R.sub.1 is methyl are disclosed as useful anti-hypertensive agents.

Abstract: Inhibitors of angiotensin converting enzyme which are physiologically acceptable salts of compounds which have the formula: ##STR1## wherein R is hydrogen, formyl, acetyl, propanoyl, butanoyl, phenylacetyl, phenylpropanoyl, benzoyl, cyclopentanecarbonyl, tert-butyloxycarbonyl, cyclopentanecarbonyl-L-lysyl, pyro-L-glutamyl-L-lysyl, L-lysyl, L-arginyl or pyro-L-glutamyl;A is phenylalanyl, glycyl, alanyl, tryptophyl, tyrosyl, isoleucyl, leucyl, histidyl, or valyl, the .alpha.-amino group thereof being in amide linkage with R;R.sub.1 is hydrogen or methyl;R.sub.2 is L-proline, L-3,4-dehydroproline, D,L-3,4-dehydroproline, L-3-hydroxyproline, L-4-hydroxyproline, L-thiazolidine-4-carboxylic acid, or L-5-oxo-proline, the imino group thereof being in imide linkage with the adjacent ##STR2## and, n is 0 or 1, such that when n is O, R.sub.1 is methyl are disclosed as useful anti-hypertensive agents.